Interface Biosciences
Founded 2020 · 2 employees on LinkedIn · 3 known investors
Interface Bio develops immunotherapies targeting complex inflammatory diseases by combining biological evolution, metabolomics, and machine learning to discover natural-derived therapeutic products.
Investors · 3
Competitors · 7
by search overlapTransition Bio7 shared keywordsTransition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Integratedbio6 shared keywordsIntegrated Biosciences is a drug discovery company developing small-molecule therapeutics for age-related diseases by combining optogenetics, synthetic biology, chemistry, and AI on its integrated platform. It focuses on probing the systems biology of aging to identify new therapeutic opportunities.
Form Bio5 shared keywordsForm Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
Emulatebio5 shared keywordsEmulate develops Organ-Chip technology, including 30+ organ models such as liver, brain, and other human tissue chips, used for human-based preclinical drug safety and toxicity testing. It serves pharmaceutical and biomedical researchers as a human-relevant alternative to animal testing, and works closely with the FDA including acceptance into the ISTAND pilot program.
Formation Bio5 shared keywordsFormation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.
Bridgebio5 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Assemblybio4 shared keywordsAssembly Bio is a biotechnology company developing antiviral therapies for serious viral and liver diseases, including treatments for recurrent genital herpes and chronic hepatitis. It focuses on virology and liver disease research to create novel drug candidates.
Companies competing with Interface Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Interface Biosciences do?
- Interface Bio develops immunotherapies targeting complex inflammatory diseases by combining biological evolution, metabolomics, and machine learning to discover natural-derived therapeutic products.
- Who are Interface Biosciences's investors?
- Interface Biosciences's investors include One Planet Group, Ulu Ventures, Pear VC.